As Fierce Pharma points out, patent expirations are a routine occurrence in the pharmaceutical world, but 2025 stands out for ...

The specter of tariffs is likely to overshadow what was a positive quarter for J&J. The company’s adjusted earnings rose 2.2% ...

Johnson & Johnson's first-quarter revenue and profit exceeded Wall Street expectations, driven by strong cancer drug sales. The company raised its 2025 sales forecast, factoring in the acquisition of ...

Johnson & Johnson has reported a strong first-quarter performance, surpassing Wall Street expectations and showcasing the power of its oncology portfolio. The company's revenue and profit both ...

Biocon Biologics Ltd (BBL), the biosimilars company and subsidiary of Biocon Ltd, has announced a licence agreement with Regeneron to commercialise Yesafili, a drug used to treat ophthalmological ...

Good morning, and welcome to Johnson & Johnson's First Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode until the question-and-answer session of the conference. This ...

It was better than Stelara in reaching ... impacting the lives of psoriasis patients,” he added. BE VIVID will follow patients for a year after starting treatment, so additional readouts will ...

The healthcare-products company on Tuesday said its higher outlook reflects its completed acquisition of mental-illness drug developer Intra-Cellular Therapies. The roughly $15 billion deal in part ...

On an adjusted basis, the company earned $2.77 per share in the quarter, 2.2 per cent higher than the previous year and above analysts' estimates of $2.59 per share ...

(Reuters) -Johnson & Johnson on Tuesday reported first-quarter revenue and profit above Wall Street estimates, driven again by strong sales of its cancer treatments including multiple myeloma medicine ...

In the Phase III ICONIC-LEAD trial, 75% of adolescents with moderate-to-severe plaque psoriasis treated with icotrokinra ...